Age Is Just a Number
Updated February 2026 | Supplemented by the NLA/AGS Expert Clinical Consensus on Managing Hypercholesterolemia in Adults >75 Years (Bittner et al., J Clin Lipidol, 2025)
Case Presentation
A 78-year-old man with a history of chronic kidney disease (stage 3), hyperlipidemia, and a severely elevated coronary artery calcium (CAC) score of 310 presents to his primary care physician for a Transitional Care Management (TCM) visit following a recent hospitalization for a non–ST-elevation myocardial infarction (NSTEMI).
During his hospitalization, he was treated appropriately by cardiology and discharged on updated guideline-directed medical therapy, including a change in statin therapy.
However, he was not scheduled for a post-discharge follow-up with his cardiologist, as the multispecialty clinic prioritizes TCM visits with primary care physicians and does not allow specialists to conduct these visits.
At the TCM appointment, the patient expresses confusion about his medications. He notes that one statin was stopped in the hospital and another started, and he is unsure which he should be taking. His primary care physician tells him that a "growing body of literature" suggests that patients his age do not benefit from statins, and suggests that he stop statin therapy altogether.
The patient leaves the visit frustrated, confused, and uncertain — unsure which medications to take, unclear about follow-up plans, and concerned that his care feels fragmented despite having just survived a heart attack.
Flying Under the Radar
1. Residual Risk After Age 75 Is Real
Older adults remain at high absolute risk for ASCVD events. While relative risk reductions may attenuate with age, absolute risk — and therefore absolute benefit — often increases. The NLA/AGS Expert Clinical Consensus (2025) confirms this with a Class I recommendation.
| Age Group | NNT to Prevent 1 MI (5 years) | NNT to Prevent 1 ASCVD Event (5 years) |
|---|---|---|
| 50–59 | 439 | 345 |
| 60–69 | 261 | 164 |
| 70–79 | 145 | 88 |
| 80–100 | 80 | 42 |
Data: Prospective Copenhagen General Study, via NLA/AGS Consensus. NNT per 1 mmol/L (~39 mg/dL) LDL-C reduction over 5 years.
2. Primary vs. Secondary Prevention Is Being Confused
This patient suffered an NSTEMI — placing him squarely in secondary prevention, where guideline consensus is clear. Stopping statins in a post-MI patient based solely on age is not guideline-supported. Three large cohort studies from France, Denmark, and Italy (aggregate N >200,000) showed that statin discontinuation was associated with an approximately 30% increase in cardiovascular admissions over 2–5 years.
3. Coronary Disease Risk Equivalents Are Being Ignored
This patient has CKD (recognized as a CHD risk equivalent) and CAC >300 (risk comparable to secondary prevention populations).
4. Systems Bias: Who Gets the Follow-Up Visit
When systems prioritize billing codes over clinical continuity, patients fall through the cracks. This represents a structural bias, not an individual failure.
March 2026 Guideline Update — Recommendations for Adults >75 Years
The 2026 Dyslipidemia Guidelines include an expanded, dedicated section addressing lipid-lowering therapy decisions in adults >75 years, reflecting the complexity and heterogeneity of this population. Key updates:
Benefit-Risk Discussion Framework: For primary prevention, clinicians should conduct formal shared decision-making addressing:
- Time-to-benefit (~2.5 years for ASCVD event reduction)
- Functional status and frailty (using validated instruments)
- Life expectancy (competing mortality risk)
- Individual patient values and preferences
De-prescribing Guidance: For patients with life expectancy <1 year from terminal illness, discontinuing statins may be reasonable to improve quality of life (COR 2b, LOE C-LD). This represents a formalization of deprescribing principles previously addressed only tangentially.
Secondary Prevention Remains Clear: For older adults with prior ASCVD events, statin continuation or intensification is evidence-based regardless of age alone (COR I).
ACC/AHA/NLA Dyslipidemia Guidelines, 2026 Update. J Am Coll Cardiol.
CAC as a Reclassification Tool in Older Adults
| CAC Score | 10-Year ASCVD Rate (MESA, Age ≥75) | Clinical Implication |
|---|---|---|
| CAC = 0 | 5.6% | Very low risk — reasonable to withhold statin (Class IIa) |
| CAC 1–99 | 14.3% | Intermediate risk |
| CAC 100–300 | 18.1% | Elevated risk — statin discussion warranted |
| CAC >300 | 24.7% | Risk approaches secondary prevention |
CardioAdvocate™ Checklist — Questions to Ask Your Doctor
Assessment Tools for Shared Decision-Making
- Clinical Frailty Scale — 9-category assessment (~3 minutes)
- Mini-Cog — brief cognitive screen (~3 minutes)
- ePrognosis — online life expectancy calculator
- Mayo Clinic Statin Choice Decision Aid — shared decision-making tool
- MESA CAC Calculator — age-, sex-, and race-based CAC scoring
Deep Dive
This is a living section — content will be updated as new evidence emerges.
The NLA/AGS Expert Clinical Consensus (2025)
The National Lipid Association and the American Geriatrics Society published a landmark Expert Clinical Consensus addressing eight key clinical questions about managing hypercholesterolemia in adults >75 without established ASCVD.
Key recommendations:
- Question 1 (Class I): LDL-C plasma level is associated with incident ASCVD and should be measured as part of ASCVD risk stratification in adults >75 without established ASCVD.
- Question 2: Traditional risk calculators have limited specificity in this age group; competing-risk adjusted models and CAC scoring refine risk assessment.
- Question 3 (Class IIb): In adults >75 with LDL-C 70–189 mg/dL, statin initiation for primary prevention may be reasonable in those without life-limiting illness.
- Question 4: Benefits of lipid-lowering with statins outweigh potential risks including SAMS, new-onset T2DM, and cognitive concerns.
- Question 5 (Class I): Validated mortality indexes incorporating comorbidities and functional status should guide decisions about life expectancy and statin benefit.
- Question 6 (Class I): LDL-C monitoring every 3–12 months; shared decision-making for all treatment decisions.
- Question 7: Deprescribing may be reasonable in select patients with life-limiting illness and estimated survival <1 year.
- Question 8: For statin-intolerant patients, ezetimibe and bempedoic acid may be considered.
CTT Meta-Analysis: What the Data Actually Show
The Cholesterol Treatment Trialists' Collaboration meta-analysis included 14,483 participants older than 75 years randomized to statin vs placebo or more intensive vs less intensive statin therapy. The absolute event rate was 1,051 (4.5%) vs 1,153 (5.0%), with an overall RR of 0.87 (95% CI 0.77–0.99).
When individuals enrolled in heart failure or dialysis trials were excluded, the absolute event rates were 4.1% and 4.7% respectively, with a RR of 0.82 (95% CI 0.70–0.95) — a statistically significant reduction.
However, when restricted to the 6,007 participants without prior vascular disease, results were attenuated (RR 0.92, 95% CI 0.73–1.16). The challenge: limited sample size and healthy volunteer bias in these subgroups.
PROSPER Trial — Often Misused
The PROSPER trial (Pravastatin in Elderly Individuals at Risk) enrolled 5,804 adults aged 70–82 years. Key findings:
- Showed a significant reduction in the primary endpoint (HR 0.85, 95% CI 0.74–0.97, p=0.014) among statin vs placebo
- Included both primary and secondary prevention patients
- The primary prevention subgroup (mean age 75) had an absolute event rate of 11.4% vs 12.1% (HR 0.94, 95% CI 0.77–1.15)
- This did NOT justify abandoning therapy in high-risk older adults — the trial was not powered for the primary prevention subgroup alone
Using this trial to justify withholding therapy is a misinterpretation of the evidence.
NNT Data: Why Absolute Benefit Increases with Age
Data from the Prospective Copenhagen General Study, highlighted in the NLA/AGS Consensus, demonstrate that the number needed to treat to prevent one event over 5 years with a 1 mmol/L (~39 mg/dL) LDL-C reduction declines with age — meaning older adults derive the greatest absolute benefit from lipid-lowering therapy. In other words, treating only 42 adults aged 80–100 for 5 years prevents one ASCVD event, compared to 345 adults aged 50–59.
Time to Benefit
Among individuals without ASCVD up to age 75 enrolled in randomized controlled outcomes trials of statin therapy, the average time to benefit was 2.5 years for reduction of ASCVD events. In older adults >80, event reduction has been observed within approximately 3 years. This directly counters the argument that "patients are too old to benefit."
CAC as a Reclassification Tool
CAC improves risk discrimination beyond age alone and is particularly useful when age dominates traditional risk calculators. The NLA/AGS Consensus provides detailed guidance:
- CAC = 0: Very low ASCVD risk. In MESA, 10-year ASCVD rate was 5.6% in those ≥75. In the CAC Consortium, 5.6-year survival rate was 98%. Reasonable to withhold statin therapy (Class IIa).
- CAC 1–99: Intermediate risk. In MESA, 10-year ASCVD rate was 14.3%.
- CAC 100–300: Elevated risk. In MESA, 10-year ASCVD rate was 18.1%.
- CAC >300: High risk. In MESA, 10-year ASCVD rate was 24.7%. Risk approaches secondary prevention populations.
Notably, using a cutoff of CAC ≥100, approximately 50% of individuals >75 will be identified as "high-risk," providing an opportunity for a risk-based discussion regarding statin therapy.
Frailty vs. Chronological Age
Frailty predicts harm; age alone does not. A healthy 85-year-old woman expected to live an additional 10 years would likely benefit from primary prevention, while a frail, multimorbid 85-year-old with less than 2 years remaining life expectancy may not stand to benefit.
The NLA/AGS Consensus (Class I) recommends that validated mortality indexes that include comorbid conditions and functional status should help clinicians incorporate the patient's remaining life expectancy into decision-making.
Critically, individuals with frailty, functional impairment, or dementia should not automatically be denied statin therapy. A retrospective cohort study of 326,981 veterans aged ≥75 without ASCVD at baseline found that new statin use was significantly associated with lower risk of all-cause and cardiovascular mortality — even at advanced ages (>90 years) and in those with dementia.
Safety Concerns Addressed
Statin-Associated Muscle Symptoms (SAMS)
The CTT Collaboration meta-analysis of SAMS included 19 double-blind trials of statin vs placebo (n=123,940). The RR of muscle-related events comparing statin and placebo treatment was 1.07 (95% CI 0.95–1.20) among those over 75 — comparable to younger age groups.
The SAMSON Trial used a crossover design with 60 participants and demonstrated that 90% of SAMS were attributable to a nocebo effect — triggered by taking a pill, not by the statin itself.
Among older patients, the Patient and Provider Assessment of Lipid Management registry (N=1,704 aged >75) found that older patients were actually less likely to report symptoms (41.3% vs 46.6%, p=0.003) than younger patients.
Cognition
While some evidence suggests statins may be associated with incident cognitive impairment in older adults, a preponderance of literature indicates neutral or even protective statin-related cognitive effects. The ASPREE trial (N=18,846, median age 74) found no association between statin use and incident dementia, MCI, or cognitive change over 4.5 years.
The NLA/AGS Consensus gives a Class IIa recommendation that it is reasonable to proceed with statin initiation despite concerns over drug-induced cognitive impairment.
New-Onset Type 2 Diabetes
Statin therapy leads to a small increase in risk of new-onset T2DM — approximately 1 new case of T2DM per 255 individuals treated with a statin for 4 years. This risk is largely confined to patients with pre-existing risk factors for T2DM. The increase in T2DM risk is outweighed by robust reductions in major cardiovascular events.
The NLA/AGS Consensus rates the benefit of statins for ASCVD risk reduction as reasonable despite the potential risk of new-onset T2DM (Class IIb, LOE B-R).
Deprescribing — When and How
Deprescribing is an important part of the prescribing continuum, but it must be done thoughtfully. The NLA/AGS Consensus provides specific guidance:
Statin discontinuation and increased ASCVD risk: Two large cohort studies showed adjusted HRs of 1.33 and 1.32 for cardiovascular events after statin discontinuation.
Cardiovascular Outcomes and Mortality Associated With Discontinuing Statins in Older Patients Receiving Polypharmacy. JAMA Netw Open.
- Life-limiting illness with estimated survival <1 year: It may be reasonable to discontinue statin therapy to improve quality of life (Class IIb, LOE C-LD).
- Shared decision-making is essential: Involving the clinician, patient, and/or caregiver is reasonable when deprescribing is considered (Class IIa, LOE C-EO).
- Communication matters: Patients prefer phrasing focused on the risk of adverse effects rather than goals of therapy when discussing deprescribing.
Non-Statin Alternatives for Older Adults
When statins are not tolerated or when additional LDL-C lowering is needed, the NLA/AGS Consensus identifies two alternatives with evidence in older patients:
Ezetimibe — EWTOPIA 75
The EWTOPIA 75 trial randomized 3,796 Japanese patients ≥75 years (mean age 80.6; 19% ≥85 years) without coronary artery disease to ezetimibe vs usual care. Results showed a 34% relative reduction in risk of MACE (2.6% absolute risk reduction, HR 0.66, 95% CI 0.50–0.86, p=0.002) in the ezetimibe group. This is the first randomized trial to demonstrate the benefit of lipid-lowering monotherapy (non-statin) exclusively in older adults.
Bempedoic Acid — CLEAR Outcomes
The CLEAR Outcomes trial enrolled statin-intolerant high-risk primary prevention patients. In the primary prevention cohort, bempedoic acid reduced the primary endpoint of major adverse cardiovascular events by 30% (absolute risk reduction 2.3%, HR 0.70, 95% CI 0.55–0.89). While 15% of participants were ≥75, specific age subgroup data have not been published. No interaction of treatment by age was observed.
Future Trials: STAREE and PREVENTABLE
Two landmark randomized controlled trials will help close the knowledge gap:
STAREE (Statin Therapy for Reducing Events in the Elderly): ~10,000 Australians aged ≥70, atorvastatin 40 mg vs placebo. Outcomes include disability-free survival, ASCVD, dementia, cancer, and quality of life. First RCT exclusively in older adults without ASCVD. Expected to complete ~December 2025.
PREVENTABLE (PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr Adults): ~20,000 community-dwelling US adults ≥75, atorvastatin 40 mg vs placebo, ~5 years. Outcomes include disability-free survival, dementia prevention, ASCVD events. Enrolling a more diverse population. Expected to complete ~December 2026.
Lifestyle: The Foundation at Any Age
Sleep: 6–9 hours per night may increase life expectancy by as much as 5 years. (ACC, 2023)
Exercise: Regular exercise can reduce risk of CHD, stroke, T2DM, and cancer, lowering early death risk by up to 30%.
Nutrition: The Mediterranean dietary style shows 24% lower CVD risk and 23% lower premature death risk with highest adherence. (Harvard T.H. Chan School of Public Health)
Mental & Emotional Health: High well-being increases survival rate by 10% even in those with chronic diseases. (NCBI — Well-Being and Longevity)
Socialization: Time to death delayed by up to 110% in those who socialized weekly vs. never. (BMJ, 2023)
Purpose: Those with the lowest sense of purpose had a 2.7x higher mortality rate from heart disease. (Harvard Health, 2019)
Think of aging as an athletic event — the more effectively you train for it, the more successful you will be. It's a retirement plan: the earlier and wiser you invest, the more likely you are to enjoy the compounding effects.
The Bottom Line
- Age does not erase cardiovascular risk.
- Secondary prevention remains evidence-based at any age. Stopping statins after a heart attack because a patient is "old" is not guideline-supported.
- Primary prevention in older adults is nuanced, not prohibited.
- NNT favors older adults: Just 42 patients aged 80–100 need to be treated for 5 years to prevent one ASCVD event.
- CKD and high CAC identify patients who need more vigilance, not less.
- CAC = 0 is reassuring: Reasonable to withhold statin therapy if CAC is 0 in uncertain cases.
- Frailty and life expectancy — not age alone — should guide decisions.
- SAMS are mostly nocebo: 90% of statin side effects are not caused by the statin itself.
- Non-statin alternatives exist.
- Systems that disrupt specialist continuity introduce hidden bias.
Age is just a number. Risk is cumulative. Prevention still matters.
